Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, Chief Legal Officer | May 13, 2024 | May 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date May 13, 2024 · Filed May 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 651,243 |
Reported balance
After 2024-05-13 transaction · row 1
1 source rowRow 1 · 2024-05-13 · Sale · Disposed 12,016 · Balance 651,243 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023. F2: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023.
F2: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2024 Filed May 14, 2024 20:05 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 12,016 | $1.26 | $15,140.16 |
DisclosureSEC source: 0001562180-24-004026 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 651,243 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023. F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:48 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 5,974 | $1.58 | $9,438.92 |
DisclosureSEC source: 0001562180-24-002022 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 663,259 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:03 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 7,411 | $1.52 | $11,264.72 |
DisclosureSEC source: 0001562180-24-001995 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 669,233 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 224,000 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001562180-24-000973 · primarydocument.xml · derivative · entry 2 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,000 Underlying: Common Stock · 224,000 shares Expires 2034-01-31 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 149,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000973 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 676,644 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2023 and 1,500 shares of the Issuer's common stock purchased on December 29, 2023, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| May 25, 2023 Filed May 26, 2023 01:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 63,186 | $1.22 | $77,270.16 |
DisclosureSEC source: 0001562180-23-004504 · primarydocument.xml · nonDerivative · entry 2 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,344 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of all of the PSUs. Read SEC document |
| May 24, 2023 Filed May 26, 2023 01:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001562180-23-004504 · primarydocument.xml · derivative · entry 3 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-05-12 F3 · derivative.exercise_date: As previously disclosed, in May 2022, the Reporting Person was granted performance-based options (the "Options") pursuant to the Issuer's 2014 Incentive Plan, as amended. The Options vest upon the closing of a significant transaction as defined in the award agreements. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the shares subject to the Option vested on May 24, 2023. Read SEC document |
| May 24, 2023 Filed May 26, 2023 01:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004504 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 587,530 F1 · shares: As previously disclosed, in May 2022, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest upon the closing of a significant transaction as defined in the award agreement. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the PSUs vested on May 24, 2023 Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004169 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,530 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 13:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,088 | $0.88 | $954.72 |
DisclosureSEC source: 0001562180-23-002200 · primarydocument.xml · nonDerivative · entry 3 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,530 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 13:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,613 | $0.88 | $5,802.91 |
DisclosureSEC source: 0001562180-23-002200 · primarydocument.xml · nonDerivative · entry 2 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,618 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 13:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 5,333 | $0.88 | $4,679.71 |
DisclosureSEC source: 0001562180-23-002200 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,231 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:05 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,677 | $0.81 | $5,429.74 |
DisclosureSEC source: 0001562180-23-002037 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,564 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. F2 · balance_after: Includes 1,500 shares of the Issuers common stock purchased on June 30, 2022, and 1,500 shares of the Issuers common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,078 | $2.17 | $2,340.01 |
DisclosureSEC source: 0001562180-22-002161 · primarydocument.xml · nonDerivative · entry 5 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,241 F5 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. F6 · balance_after: Includes 1,500 shares of the Issuers common stock purchased on June 30, 2021 and 1,500 shares of the Issuers common stock purchased on December 31, 2021, each under the Issuers 2014 Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,556 | $2.17 | $14,231.11 |
DisclosureSEC source: 0001562180-22-002161 · primarydocument.xml · nonDerivative · entry 4 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,319 F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 02:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,873 | $2.17 | $14,919.22 |
DisclosureSEC source: 0001562180-22-002161 · primarydocument.xml · nonDerivative · entry 3 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,875 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 200,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001562180-22-002161 · primarydocument.xml · derivative · entry 6 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-28 F7 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-002161 · primarydocument.xml · nonDerivative · entry 2 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,748 F2 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:10 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,555 | $2.15 | $14,124.71 |
DisclosureSEC source: 0001562180-22-002161 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,748 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 00:33 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,060 | $3.40 | $3,604.00 |
DisclosureSEC source: 0001562180-21-002542 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,303 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:18 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 10,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-002356 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,363 F1 · shares: As previously disclosed, in February 2020, the Reporting Person was granted performance-based restricted stock unit awards ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest in connection with the achievement of specified commercial and regulatory milestones. On February 25, 2021, the Company reported its financial results for the year ended December 31, 2020. Subsequently, in accordance with the terms of the grant, the Issuer's Compensation Committee certified the achievement of a commercial milestone and, as a result, one third of the reported PSUs will vest on each of March 31, 2021, February 28, 2022 and February 28, 2023, subject to the Reporting Person's continued service with the Issuer on each vesting date. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 7,976 | $3.40 | $27,087.29 |
DisclosureSEC source: 0001562180-21-001785 · primarydocument.xml · nonDerivative · entry 3 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,171 F4 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,309 | $3.40 | $21,425.99 |
DisclosureSEC source: 0001562180-21-001785 · primarydocument.xml · nonDerivative · entry 2 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,147 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 110,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001562180-21-001785 · primarydocument.xml · derivative · entry 4 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2031-02-26 F5 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 62,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001785 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,456 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2020 and 1,200 shares of the Issuer's common stock purchased on December 31, 2020, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 00:28 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 105,000 | $0.00 Strike: $8.87 | $0.00 |
DisclosureSEC source: 0001562180-20-001936 · primarydocument.xml · derivative · entry 3 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2030-02-28 F4 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 00:28 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 7,050 | $8.70 | $61,335.00 |
DisclosureSEC source: 0001562180-20-001936 · primarydocument.xml · nonDerivative · entry 2 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,756 F3 · shares: This sale was made to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 00:28 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 62,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-001936 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,806 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. F2 · balance_after: Includes 1,500 shares of the Issuer's common stock purchased on June 28, 2019 and 1,500 shares of the Issuer's common stock purchased on December 31, 2019, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 20:00 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Disposition to issuerCommon Stock | 11,929 | $7.70 | $91,853.30 |
DisclosureSEC source: 0000899243-19-010589 · doc4.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,806 F1 · shares: The proceeds from the disposition of these shares are to be used by the reporting person to cover tax liabilities associated with previously vested restricted stock units. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 21:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 100,000 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001562180-19-001676 · primarydocument.xml · derivative · entry 2 Hadas Nicole R. · CIK 0001602396 · SVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-02-28 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 21:06 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-001676 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,735 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date. F2 · balance_after: Includes 451 shares of the Issuer's common stock purchased under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 13:15 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | Tax withholdingCommon Stock | 20,175 | $8.94 | $180,364.50 |
DisclosureSEC source: 0000899243-18-030794 · doc4.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,284 F1 · balance_after: Includes 1,381 shares acquired under the Akebia Therapeutics, Inc. stock purchase plan on June 29, 2018. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:15 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantEmployee Stock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $14.30 | $0.00 |
DisclosureSEC source: 0001562180-18-001385 · primarydocument.xml · derivative · entry 2 Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-28 F3 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2014 Incentive Plan. 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:15 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-001385 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,078 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date. F2 · balance_after: The total amount of beneficial securities owned includes 774 shares of stock purchased on December 31, 2017 at $12.39 per share in connection with the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:21 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 6,250 | $19.95 | $124,687.50 |
DisclosureSEC source: 0001562180-17-003206 · primarydocument.xml · nonDerivative · entry 2 Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,804 F2 · shares: Shares sold by Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:21 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,553 | $19.64 | $30,500.92 |
DisclosureSEC source: 0001562180-17-003206 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,054 F1 · shares: Shares sold by Reporting Person pursuant to a Rule 10b5-1 trading plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 restricted stock award. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 16:24 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,554 | $14.26 | $22,156.47 |
DisclosureSEC source: 0001562180-17-002434 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,607 F1 · shares: Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.11 to $14.41, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. F3 · balance_after: The total amount of beneficial securities includes 1,305 shares of stock purchased on June 30, 2017 at $8.92 per share in connection with the Issuer's Employee Stock Purchase Plan. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 20:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,556 | $9.18 | $14,280.19 |
DisclosureSEC source: 0001562180-17-001429 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,856 F1 · shares: Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.15 to $9.24, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 21:02 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 45,000 | $10.14 Strike: $0.00 | $456,300.00 |
DisclosureSEC source: 0001562180-17-000880 · primarydocument.xml · derivative · entry 2 Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-02-21 F2 · derivative.exercise_date: 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 21:02 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 28,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-000880 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,412 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date. Read SEC document |
| January 01, 2017 Filed Jan 3, 2017 21:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,810 | $10.49 | $18,987.99 |
DisclosureSEC source: 0001562180-17-000080 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,912 F1 · shares: Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017. F2 · balance_after: The total amount of beneficial securities includes 807 shares of stock purchased on December 30, 2016 at $6.48 per share in connection with the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 01, 2016 Filed Oct 4, 2016 20:12 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 1,556 | $8.95 | $13,933.67 |
DisclosureSEC source: 0001562180-16-003206 · primarydocument.xml · nonDerivative · entry 1 Hadas Nicole R. · CIK 0001602396 · SVP, General Counsel, Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,915 F1 · shares: Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through December 2, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.